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Serum sickness-like reaction associated 
with clopidogrel
 
Clopidogrel (Plavix
 
®
 
) is a selective inhibitor of platelet
aggregation used preventively in the setting of myocardial
infarction, coronary stent implantation and stroke [1].
Clopidogrel structurally resembles another thienopyri-
dine antiplatelet drug ticlopidine (Ticlid
 
®) differing only
by the presence of a carboxymethyl side group on clo-
pidogrel. The drugs differ in their toxicity profile, with
ticlopidine being more significantly associated with hae-
matological adverse events such as agranulocytosis [2].
Recent reports have described a syndrome of arthritis
and rash or pruritus associated with both clopidogrel and
ticlopidine [3, 4]. We describe a case of serum sickness-
like reaction (SSLR) associated with clopidogrel that
along with the earlier reports, highlights that SSLR may
be an uncommon but potentially underreported adverse
event associated with the thienopyridine antiplatelet
drugs.
A 51-year-old man presented with an acute coronary
syndrome. Longstanding medications included atorvas-
tatin, metoprolol and enteric coated aspirin 325 mg
daily.
Subsequent cardiac catheterization revealed an angio-
plastable lesion. Following the insertion of a coronary
artery stent, he was started on clopidogrel 75 mg once
daily. Ten days later he developed fever followed by
arthralgias and skin rash. Physical examination revealed
an exanthematous rash over the chest and back and stress
pain of the shoulder and knee joints bilaterally. Complete
blood count, liver function tests, creatinine and urine
microscopy were normal. Symptoms resolved over a
week with discontinuation of clopidogrel and a tapering
dose of prednisone. He remains on atorvastatin, aspirin
and metoprolol.
The constellation of fever, arthritis, and rash occurring
10 days following initiation of a new drug support the
diagnosis of clopidogrel-associated SSLR. Other recent
reports suggest that SSLR may be associated with both
clopidogrel and ticlopidine [3, 4]. Dakik 
 
et al.
 
 reported
a 65-year-old woman who developed an urticarial rash
and arthritis 12 days after starting ticlopidine 250 mg
twice daily after coronary artery stent placement [3]. The
authors labelled this as ‘hypersensitivity vasculitis’; how-
ever, the time sequence, arthritis, urticarial rash and lack
of internal organ involvement are most consistent with
SSLR. Garg 
 
et al.
 
 described two cases of ‘arthritis’ asso-
ciated with clopidogrel. One was a 76-year-old woman
who developed pruritus and symmetrical polyarthritis
2 weeks after starting clopidogrel following coronary
stent insertion [4]. The second case was a monoarthritis
occurring 3 weeks after initiation of clopidogrel and may
have been unrelated to drug [4]. In all cases the symp-
toms were self-limited with no recurrence after discon-
tinuation of ticlopidine and clopidogrel, respectively [3,
4]. Although cutaneous reactions and arthritis have been
associated with both clopidogrel and ticlopidine in post-
marketing reports, no specific cases of SSLR have been
reported. The structural similarity between clopidogrel
and ticlopidine would suggest the potential generation of
similar, although as yet unidentified, reactive metabolites.
These metabolites along with immunological and host
factors are thought to be important for the pathophysi-
ological basis of SSLR [5]. Interestingly, bupropion
(Zyban
 
®), an antidepressant which has also been associ-
ated with SSLR, shares some structural features with
clopidogrel and ticlopidine, although the putative reactive
metabolite is unknown [6].
Although none of the cases, including ours, was
rechallenged with the drug in question, these cases
should increase awareness of a potential association
between ticlopidine and clopidogrel and SSLR.
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